ENABLING PRECOMPETITIVE TRANSLATIONAL RESEARCH: A CASE STUDY - Collaborative Computational Technologies for Biomedical Research - page 259

Target
Validation

Phase II &
III

Target ID Lead ID Preclinical Biomarker Phase I Phase IV

Pharmaco-
vigilance
DB

Assay
DB

Biomarker
DB

Pharmacology
DB

Omics DB PK/PD DB Clinical DB

Target DB

tranSMART

Figure 16.13 tranSMART integrates data from multiple data silos across the drug
discovery and development process.

ACKNOWLEDGMENTS

We wish to thank the following individuals for their outstanding effort and dedication
during the tranSMART project: Eric Perakslis, Jason Smart, Greg Leibfreid, Robert
Gruninger, John Boles, George Kuebrich, Dorian Tisdale, Venkat Koka, Eudean Shaw,
Hongtao Fan, Xiang Yao, Jean-Marc Neefs, Hans Winkler, Elliot Barnathan, Anuk Das,
and Chris Ward (employees of the pharmaceutical companies of Johnson and Johnson);
Dan Housman, Bruce Johnson, Jinlei Liu, Joe Adler, Anthony Ioven, Tarang Jatkar,
Jean Avitable, Haiping Xia, and Aaron Mandel (employees of Recombinant Data
Corporation); Tatiana Khasanova and Svetlana Bureeva (employees of GeneGo); and
Gyan Bhanot and Joe Irgon (Rutgers University).

REFERENCES

1. Seventh Framework Programme . http://ec.europa.eu/research/fp7/index_en.cfm?
pg=health .
2. Stoffels P . Collaborative innovation for the post - crisis world . The Boston Globe
2009 ;February 2, A13.
3. Friend SH . The need for precompetitive integrative bionetwork disease model
building . Clin Pharmacol Ther 2010 ; 87 : 536 - 539 .
4. Hunter J , Stephens S . Is open innovation the way forward for big pharma? Nature
Rev Drug Disc 2009 ; 9 : 87 - 88 .
5. Barnes MR , et al. Lowering industry fi rewalls: Pre-competitive informatics initia-
tives in drug discovery. Nature Rev Drug Disc 2009 ; 8 : 701 - 708 .